Unicycive Therapeutics effects 1-for-10 reverse stock split to regain Nasdaq compliance

Unicycive Therapeutics, Inc.

Reverse stock split at 1-for-10 ratio effective June 18, 2025; begins trading split-adjusted June 20, 2025.
Reduces outstanding shares from ~126.4M to ~12.6M; no fractional shares (rounded up).
CUSIP changes to 90466Y 202; symbol remains UNCY.
Board authorized reverse split on June 9, 2025; split intended to meet $1.00 minimum bid price for Nasdaq listing.
Proportional adjustments to stock options, warrants, and preferred stock conversion prices.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Unicycive Therapeutics, Inc.: Filed a Certificate of Amendment to effect a 1-for-10 reverse stock split of Common Stock (effective 2025-06-18).

Change: charter amendment
Effective: 2025-06-18

Exact text from the filing

On June 18, 2025, the Company filed the Charter Amendment with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split.

View on SEC.gov

Browse all governance changes →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-056188

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.